Patent 7893061 was granted and assigned to Amgen on February, 2011 by the United States Patent and Trademark Office.
The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I